Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery. With tech-enabled therapies evolving fast, new inflection points spell a ...

A FAT jab user has revealed that after stopping the injections for eight weeks, she has now realised she is a “Mounjaro lifer ...

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB ...

New data from The Ohio State University Wexner Medical Center Comprehensive Transplant Center shows obese patients with end stage kidney disease and diabetes can safely use weight loss injections to ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...